To determine whether FLT3L-preconditioned CD44high CD8 T cells could provide better control of tumors, we performed adoptive cell transfer (ACT) therapies in poorly immunogenic Ova-expressing B16 and E.G7 syngeneic tumor models (Fig. 3A). This evidence concerns the gene FLT3LG and neoplasm.